Chief Scientific Officer Job Description (CSO) for International Biotech and Life Sciences Companies

Regulatory pathways and FDA requirements change. This is not regulatory advice. Consult qualified FDA regulatory counsel.

At Pact & Partners, we specialize in placing Chief Scientific Officers for international life sciences and biotech companies building R&D capabilities in the United States. Founded 1987. research.

A Chief Scientific Officer is not your VP of R&D. They’re not your Head of Medical Affairs. They’re the strategic voice that translates science into competitive advantage — the person who sits between your board and your lab. Most companies get this hire wrong. They either recruit someone overqualified in credentials but underprepared for US regulatory complexity, or they find a domestic candidate who doesn’t understand international R&D integration.

What a CSO Actually Does (It Changes by Stage)

The CSO role is deceptively simple on paper: oversee scientific strategy, validate R&D priorities, own the scientific narrative to investors, partners, and regulators. In practice, it’s three different jobs depending on company maturity.

Pre-clinical biotech: The CSO is the chief strategist. 

They decide which targets to pursue, which animal models matter, whether your science story holds up to investor scrutiny. They’re not running the bench — they’re explaining why the bench work matters. You need someone with deep scientific credibility and serious business intuition. A Nobel Prize doesn’t help if they can’t explain in 10 minutes why your molecule is better than three competitors.

Clinical-stage company: The CSO bridges R&D and regulatory. 

They know FDA guidance intimately. They design Phase II studies with the CMO. They understand which data packages will move regulatory needles and which are noise. They defend scientific choices to your board when timelines slip. They’re often the public face of your science at investor conferences.

Commercial-stage pharma or larger biotech: The CSO is a peer to the CMO and COO. 

They own portfolio strategy, pipeline sustainability, the scientific moat around marketed products. They think about line extensions, new indications, whether your R&D spend actually generates competitive IP. They manage senior scientists and potentially multiple therapeutic areas.

The mistake most companies make: hiring for one stage and pretending they’ve hired for another. 

A CSO brilliant at pre-clinical strategy crumbles under regulatory pressure. A CSO excellent with the FDA doesn’t know how to build sustainable R&D portfolios. A CSO who ran large pharma programs lacks the hustle of clinical biotech.

Why US Subsidiaries Need Different CSOs

This is where we see the biggest hiring mismatches. A European or Japanese pharma parent will try to transplant their global R&D head into a US subsidiary role — or recruit a US CSO without understanding how the position differs from HQ.

The global R&D head at your parent company oversees pipeline management across multiple regions. They attend regulatory hearings in Amsterdam, conduct development planning that balances US, EU, and Japanese timelines, work with corporate R&D infrastructure spanning continents. That person is a scientist-executive managing enormous complexity.

A CSO in a US subsidiary does something much narrower and much more specific. They’re accountable for US regulatory strategy, US clinical trial management, US commercial partnerships. They report to a regional president or directly to global R&D, but don’t have the same resource pools. They can’t call Europe to borrow a safety database; they own US safety data. They can’t defer regulatory questions to Amsterdam; US regulators expect them to own it.

Here’s what breaks most of these placements: The parent company assumes the US CSO can handle it because “it’s just America.” America is not just anything when it comes to drug development. The FDA has specific expectations about in-person engagement, who holds the IND, contingency planning. A CSO from a centralized European system often misreads these expectations and either moves too slowly (coordinating across multiple regions) or too fast (impatient with what feels like redundant US paperwork).

We’ve placed CSOs who thrived because they had prior US regulatory experience. They understood that “getting FDA alignment” isn’t a box you check in Amsterdam and apply globally. It’s something you do directly, repeatedly, with specific scientific and regulatory judgment happening in real time.

Core Responsibilities by Company Stage

Series A–B biotech

• Define and defend scientific strategy; narrow your target portfolio ruthlessly
• Design clinical development plans that satisfy FDA expectations without burning cash
• Lead scientific advisory board recruitment and manage those relationships
• Prepare for initial FDA meetings
• Write the scientific sections of funding presentations
• Validate whether your lead program’s data supports your claims
• Coach the CEO on how to talk about science without bullshit

Phase II–Phase III clinical biotech

• Manage interactions with the FDA; own Type C and Type D meeting strategy
• Design Phase II and III protocols with the CRO and internal team
• Set go/no-go criteria for clinical progression
• Manage the scientific relationship with your Data and Safety Monitoring Board
• Oversee regulatory submissions and CMC (chemistry, manufacturing, and controls) strategy
• Build and maintain external advisory relationships with key opinion leaders
• Present at investor and partnership meetings; own the narrative around clinical readouts

Commercial or larger biotech

• Set portfolio strategy and prioritize R&D spend across programs
• Manage the CMO, VP R&D, and potentially multiple therapeutic area heads
• Own competitive intelligence and market science strategy
• Design lifecycle management strategies for marketed products
• Identify partnership and licensing opportunities
• Represent the company’s scientific position to investors, partners, and acquired entities
• Manage IP strategy and ensure freedom-to-operate assessments

Compensation by Company Stage

These figures reflect 2025-2026 market rates for US-based CSOs at biotech and specialty pharma companies, sourced from PayScale, Glassdoor, and Comparably compensation databases. They assume a fully engaged role — meaning the CSO is on-site, directly accountable, and not part-time.

Series A–B biotech: $280K–$350K base + 25–40% bonus + 0.5–1.5% equity = $350K–$490K total

Series C–D biotech: $340K–$450K base + 30–50% bonus + 0.3–1.0% equity = $440K–$675K total

Phase II–III clinical: $400K–$530K base + 35–60% bonus + 0.25–0.75% equity = $540K–$850K total

Commercial-stage biotech: $480K–$650K base + 40–75% bonus + 0.1–0.5% equity = $672K–$1.1M total

Specialty pharma: $540K–$800K base + 50–100% bonus + 0.05–0.2% equity = $810K–$1.6M total

Geographic premium: CSOs in San Jose, CA command approximately 15–20% premiums above these ranges. Boston, San Francisco, and San Diego markets similarly show 12–18% above national averages.

Notes on these ranges:

Early-stage companies trade lower base salaries for higher equity stakes. A CSO joining a Series A round at $280K base might get 1.2% fully diluted — worth significant value if the company succeeds, nothing if it fails.

Larger companies and well-funded later-stage companies offer higher bases and lower equity. A CSO at a commercial-stage biotech with $120M revenue might earn $550K base + $275K bonus, but only 0.2% equity.

Geographic location matters. A CSO in San Francisco or Boston commands 15–20% premiums over the same role in Minneapolis or Indianapolis. Post-pandemic, secondary biotech hubs now offer 10–15% above traditional Midwest rates to compete.

International assignment affects compensation. A CSO on US assignment from a foreign parent might negotiate US-level salary but keep some international benefits (often a mistake on both sides). We typically recommend resetting to US market rates and ending the international package entirely for tax and retention clarity.

Three Hiring Mistakes We See Repeatedly

Mistake 1: Overweighting academic credentials, underweighting regulatory judgment.

You see a CV: “PhD from Cambridge, postdoc at Stanford, 15 papers in Nature and Science, seven years as a professor.” You think you’ve found your scientist. You’ve often found someone brilliant at asking new questions but terrible at answering predetermined ones.

Drug development isn’t about generating novel science. It’s about executing against an agreed regulatory pathway with the FDA or EMA. A CSO who spent 15 years publishing probably spent zero years explaining their work to regulators or managing clinical trials against predefined endpoints.

We’ve placed CSOs with less impressive academic pedigrees than candidates we passed on — and they succeeded because they understood FDA guidance, had run a Phase III trial, could translate scientific complexity into regulatory language. One CSO we placed had a strong but not stellar publication record, but worked as a medical officer at the FDA for three years. That FDA experience was worth more than an extra 20 papers.

What to look for instead: Ask candidates to walk you through a Phase II clinical trial they participated in. Ask them to explain an FDA comment letter they received and how they responded. Ask them to describe a moment when they had to choose between what would make a good paper and what would satisfy a regulator. You’ll quickly tell who has real regulatory judgment.

Mistake 2: Hiring a CSO without confirming their authority over R&D.

You hire a CSO and give them a beautiful title. Then your VP R&D — who’s been there five years and manages the actual scientists — views the CSO as a threat. Or your Chief Medical Officer thinks the CSO reports to them. Or your CEO treats the CSO as a senior consultant who advises but doesn’t decide.

CSO authority has to be crystal clear before you hire. The CSO needs to own scientific strategy, which means they need the authority to redirect R&D resources, kill programs, reset timelines. If your VP R&D can argue with every strategic call the CSO makes, you’ve hired an expensive advisor, not a leader.

What to fix: Before posting the role, define exactly what the CSO owns and what reports to them. Is it R&D alone, or R&D + regulatory? Do they have dotted-line authority over the CMO on protocol design? Can they override a program manager’s timeline assessment? Document this and share it with final candidates. Then, when you hire, your CEO needs to signal — loudly and clearly — that the CSO has final say on scientific strategy.

Mistake 3: Hiring for your current stage, not your next one.

A Series B biotech hires a CSO because they need someone to navigate early FDA meetings. So they recruit an excellent former FDA officer great at regulatory interpretation. Then eighteen months later, the company raises Series C and suddenly needs someone who can manage a larger R&D organization, set portfolio strategy, think about competitive positioning. The FDA expert is lost.

Companies need CSOs who can grow with them — or they need to accept they’re hiring for a two-to-three-year window and then need to upgrade.

What to fix: During the interview process, explicitly talk about the next phase. Ask candidates whether they’ve managed career transitions like this. Look for CSOs who have experience across multiple company stages, not just deep expertise in one. A CSO who’s moved from Phase I biotech to Phase III to commercial has already proven they can adapt.

Academia vs. Industry: Choose Based on Your Stage

Choose Academia-to-Industry If:

• You’re pre-clinical or early clinical and need someone to design studies and validate science credibility
• Your scientific advisory board is weak and you want a CSO who brings their own network
• You’re in a scientifically novel area where deep domain expertise matters more than regulatory experience
• You can accept a 6–12 month ramp-up period while they learn internal processes
• Your CEO or board is strong enough to guide regulatory judgment (your CSO won’t have it)
• You need someone who can still publish and enhance your company’s academic visibility

Choose Industry-Experienced If:

• You’re clinical-stage or beyond and navigating FDA heavily
• You need someone who can manage CMC, pharmacovigilance, post-market safety
• Regulatory judgment is more valuable than novel science generation
• You want minimal ramp-up; they should contribute on day one
• You’re a subsidiary of a foreign parent and need someone who understands US regulatory norms
• You’re planning an exit or partnership and need someone who speaks pharma deal language

The hybrid option:

Some companies hire a CSO with industry experience and a Chief Scientific Advisor from academia — typically an unpaid or modestly paid advisory role. The CSO runs the business; the advisor brings scientific credibility and networks. This works well if the advisor actually has enough credibility to influence strategy (and isn’t just a trophy name).

How We Approach CSO Placements

We’ve placed CSOs across every company stage, from pre-clinical biotech to commercial pharma. We understand the cross-border complexity because we’ve helped European, Japanese, Canadian, and Australian companies hire their first US CSO. We know what skills transfer and what doesn’t. We know which academic backgrounds actually predict success and which impress on paper but disappoint in practice.

We’ve also seen what breaks placements: misaligned authority, unrealistic regulatory expectations, CSOs who can’t adapt to growth, hiring managers who define the role poorly before the search begins.

Learn more about how we approach executive search.

CSO (Chief Scientific Officer) Compensation — U.S. Life Sciences (2024–2025)

Sources: Korn Ferry, Radford, BioSpace (2024–2025 data)

For foreign pharmaceutical and biotech companies hiring U.S.-based CSOs, the regulatory knowledge requirement is non-negotiable. The FDA's regulatory framework — including the IND application process, breakthrough therapy designation, accelerated approval pathways, and post-marketing requirements — differs significantly from the EMA (European Medicines Agency) framework or the PMDA (Japan) framework. A CSO who has navigated FDA interactions through multiple clinical programs brings institutional knowledge that cannot be acquired through training alone.

The 'valley of death' in translational medicine — the gap between basic scientific discovery and successful clinical development — has been extensively studied by institutions including the NIH's National Center for Advancing Translational Sciences (NCATS). Research published in Nature Reviews Drug Discovery (2012) found that approximately 90% of drug candidates fail in clinical trials, with the majority of failures occurring in Phase II due to lack of efficacy rather than safety concerns. The CSO who can reduce this attrition rate by even a few percentage points — through better target validation, biomarker-driven patient selection, or adaptive trial design — creates billions of dollars in shareholder value.

Thomas Kuhn's The Structure of Scientific Revolutions (University of Chicago Press, 1962) introduced the concept of 'paradigm shifts' — the observation that scientific progress is not incremental but occurs through revolutionary reconceptualizations of fundamental assumptions. For CSOs managing research portfolios in rapidly evolving fields like gene therapy, mRNA therapeutics, or AI-driven drug discovery, Kuhn's framework is a practical management tool: the CSO must assess whether a new technology represents a true paradigm shift requiring portfolio reallocation or merely an incremental improvement within the existing paradigm.

The Chief Scientific Officer occupies perhaps the most intellectually demanding position in the life sciences C-suite. As Donald Stokes argued in Pasteur's Quadrant: Basic Science and Technological Innovation (Brookings Institution Press, 1997), the most valuable scientific work occurs at the intersection of fundamental understanding and practical application — what Stokes called 'use-inspired basic research.' The CSO must cultivate this intersection, ensuring that the company's scientific portfolio includes projects with both near-term clinical value and long-term platform potential.